Background. Repeated immunizations with polysaccharide (PS) vaccines cause hyporesponsiveness through undefined mechanisms. We assessed the effects of a PS booster on immune responses, frequency, and survival of PS-specific B-cell subpopulations in spleen and bone marrow.
1
) MenC-PS-specific naive B cells (CD138 2 /B220 1 ; P 5 .0003) and plasma cells (CD138 1 /B220 2 ; P 5 .0002) in spleen were fewer than after saline booster. BrdU Conclusions. We demonstrated that the MenC-PS booster significantly reduced the frequency of newly activated MenC-PS-specific B cellsdmostly switched IgG 1 memory cellsdby driving them into apoptosis. It shows directly that apoptosis of PS-specific memory cells is the cause of PS-induced hyporesponsiveness. These results should be taken into account prior to consideration of the use of PS vaccines.
Polysaccharide (PS) vaccines have been available against some serogroups of Neisseria meningitidis (meningococcus) since the 1960s; however, outbreaks still occur, the last in 2009 [1] . With improved treatment, the case fatality rate of meningococcal disease has decreased from 70%-90% to approximately 10% [2] if patients are treated with the appropriate antibiotics.
In 1975 it was observed that repeated immunizations with a capsular PS of meningococcus serotype C (MenC) induced hyporesponsiveness in infants [3] . This was confirmed in Gambian children who received plain MenC-PS boosters [4] . The effect was long-lasting. Children who were primed as infants with a meningococcal C conjugate MenC-CRM 197 booster experienced, at 5 years of age, a reduced MenC-PS-specific antibody response and serum bactericidal activity (SBA) following a MenC-PS booster at 2 years of age, compared with children who were given MenC-CRM 197 or saline [5] . MenC-PS-induced hyporesponsiveness has been observed in additional studies in infants [6] [7] [8] and adults [9] [10] [11] . Hyporesponsiveness has also been observed for MenA [12] , and recent data indicate that serogroups W-135 and Y may induce hyporesponsiveness (reviewed in [13] ).
Although PS-induced hyporesponsiveness has been known for decades, the mechanisms that cause it are poorly defined. A common theory is that PSs deplete the memory B-cell pool [5, 14, 15] . Understanding the mechanisms that cause PS-induced hyporesponsiveness is important because PS vaccines are recommended for children at risk of invasive bacterial diseases, and PS boosters are used to demonstrate that conjugate vaccines have induced memory. Polysaccharides are also given to elderly people at increased risk of infectious diseases [16] , which may not have the desired effects if the PS has detrimental effects on immune memory.
The aim of this study was to evaluate the effects of MenC-PS booster on the immune responses of mice primed with the MenC-CRM 197 as neonates and to assess the survival of MenC-PS-specific memory B cells, in spleen and bone marrow, by using a fluorochrome-labeled MenC-PS, markers identifying B-cell subpopulations, and Annexin V to label apoptotic cells.
MATERIALS AND METHODS

Animals
NMRI mice (M&B) were kept in microisolator cages with free access to food pellets and water and housed under standard conditions with regulated daylight, humidity, and temperature. Breeding cages were checked daily, and pups were kept with their mothers until weaning. The study was authorized by the Animal Experimental Committee of Iceland.
Vaccines and Adjuvants
Meningococcal oligosaccharide C conjugated to CRM 197 [17] (MenC-CRM 197 ) and MenC-PS were provided by Novartis Vaccines and Diagnostics. CpG2006 and CpG1826 were purchased from Oligos, Etc.
Experimental Setup
In the first set of experiments (3 independent experiments), neonatal mice (1 week old, 8-9 per group) were immunized subcutaneously in the scapular girdle with 2 primary doses of monovalent MenC-CRM 197 (2.5 lg/dose) and CpG2006 (100 lg/dose, except for the first dose of 20 lg/dose [18] ), at 1 and 3 weeks of age. The mice were boosted at 5 weeks of age with MenC-CRM 197 1CpG2006, saline1CpG2006, or MenC-PS (10 lg/dose)1CpG2006. Mice that received saline or MenC-CRM 197 without CpG2006 were used as controls. A second MenC-PS1CpG2006 booster was administered to all groups (13 weeks of age). Mice were bled from the tail vein weekly from 3 weeks of age; serum samples were isolated and stored at 220°C until use. In the second set of experiments, mice were immunized as in the first, except that for priming, CpG1826 was used instead of CpG2006, and no adjuvant was given with the boosters. To label proliferating cells, the mice received intraperitoneal injections of BrdU (1.5 ug) at the booster day and daily, until they were killed 8 hours, 12 hours, 24 hours, 48 hours, and 5 days later, when spleen and bone marrow were removed for enumeration and phenotyping of MenC-PS-specific B cells.
Antibody Measurements
MenC-PS-specific immunoglobulin G (IgG) was measured by enzyme-linked immunosorbent assay (ELISA) [19] . ELISA plates (MaxiSorp, Nunc) were coated with 5 lg/mL MenC-PS (Novartis Vaccines and Diagnostics) in phosphate-buffered saline (PBS) with methylated human serum albumin (5 lg/mL) overnight (4°C), blocked with 1% gelatin (BDH Chemicals) in PBS for 3 hours at 37°C, and fixed with 10% saccharose (Merck) and 4% polyvinylpyrrolidone (Sigma) for 2 hours. Serial dilutions of samples and standards in PBS-Tween-1% BSA (Sigma) were incubated overnight at 4°C, followed by horseradish peroxidase-conjugated goat anti-mouse IgG (Southern Biotechnology) and developed by 3.3#,5.5#-tetramethylbenzidine substrate (Kirkegaard and Perry Laboratories). The reaction was stopped with 0.18 mol/L H 2 SO 4 and absorbance read at 450 nm with an ELISA spectrophotometer (Original Multiscan Ex, Thermo Electron Corporation). Results were calculated from standard (hyperimmunized serum) and assigned a titer of the inverse dilution, which gave an optical density (OD) of 1.0.
Avidity of MenC-PS-specific IgG was measured by the same ELISA, including KSCN incubation (serial dilutions: 7.5-0.117 mol/L) or PBS-Tween (100% binding) for 15 minutes after the serum incubation. Bound antibodies were detected with alkaline phosphatase-conjugated goat antimouse IgG (Southern Biotechnology) and p-NPP (Sigma) and absorbance read at 405 nm. Results are expressed as avidity index (AI) 5 [mol/L] KSCN that displaces 50% of antibodies.
Serum Bactericidal Activity
SBA was measured in serum pools from each group (equal volumes per mouse) [20] . N. meningitis strain C11 was grown overnight at 37°C on chocolate agar plates with 5% CO 2 colonies inoculated into 7 mL Mueller-Hinton broth containing 0.25% glucose to reach an OD at 600 nm of 0.05-0.06; it was then incubated 1.5 hours at 37°C with 5% CO 2 until the OD at 600 nm reached 0.23-0.24. Bacteria were diluted in Grey's salt solution (Sigma) and 1% BSA (Sigma) at 10 5 colony-foruming units /mL. The reaction mixture contained 25 lL of serum dilution, 12.5 lL of bacteria, and 12.5 lL of baby rabbit complement. Controls included 1) bacteria with complement, 2) bacteria with immune sera and complement inactivated at 56°C for 30 minutes. Immediately after complement addition, controls were plated on MuellerHinton agar plates using the tilt method (time 0) and then incubated for 1 hour at 37°C with 5% CO 2 . Samples were transferred to Mueller-Hinton agar plates as spots and controls transferred using the tilt method (time 1) were incubated for 18 hours at 37°C with 5% CO 2. Colonies corresponding to time 0 and time 1 were counted, and reciprocal serum dilutions killing 50% of bacteria were calculated.
Cell Isolation and Flow Cytometry
Single-cell suspensions were prepared from spleen and bone marrow by filtering through a 70-lm cell strainer (BD Biosciences) and Histopaque-1077 (Sigma) gradient centrifugation. 
Statistical Analysis
Nonparametric Mann-Whitney U test was used, and a P value of ,.05 was considered statistically significant.
RESULTS
A MenC-PS Booster Elicited Lower Antibody Levels, Affinity, and SBA Than MenC-CRM 197 and Reduced Response to a Second MenC-PS Booster Neonatal mice (1 week old) were immunized with 2 primary doses of MenC-CRM 197 together with CpG2006 as an adjuvant and boosted as adult mice (5 weeks old) with MenC-CRM 197 , saline, or MenC-PS, all with CpG2006. A second MenCPS1CpG2006 booster was given to all groups at 13 weeks of age.
The first MenC-CRM 197 booster induced higher MenC-PSspecific IgG levels than did MenC-PS (P 5 .0006) or saline (P 5 .0061); the levels persisted after the second booster. Antibody levels were comparable in mice that received saline or MenC-PS booster; these persisted after the second booster ( Table 1 ). The MenC-CRM 197 booster induced a 16-fold increase in SBA (Table 1) , but MenC-PS induced a 2-fold increase. SBA declined until the second MenC-PS1CpG2006 booster at week 13. The first MenC-CRM 197 booster induced higher antibody AI than did MenC-PS (P 5 .009) or saline (P 5 .031). After the second MenC-PS1CpG2006 booster, the AI increased in mice that received MenC-CRM 197 or saline at 5 weeks. In contrast, MenC-CRM 197 than in mice that received MenC-PS or saline booster in both bone marrow (P 5 .0031 and P 5 .0216, respectively) and spleen (P , .001 and P 5 .002, respectively).
Mice that received MenC-PS booster had lower frequency of BrdU 1 MenC-PS-specific B cells in spleen than did mice that received saline (P , .0012), whereas there was no difference in the bone marrow ( Figure 1) . We therefore evaluated which MenC-PS-specific B-cell populations were reduced by the MenC-PS booster.
MenC-PS Booster Did Not Induce Full Differentiation of MenC-PS-Specific Memory B Cells Into Plasma Cells
MenC-PS-specific B-cell subpopulations in spleen and bone marrow were studied after MenC-PS, MenC-CRM 197 , and saline boosters. B220 was used as a B-cell marker, which is expressed on early B cells and memory B cells but not on plasma cells. B-cell subpopulations were further identified by using CD138, which is expressed on plasmablasts/memory cells and plasma cells but not on naive B cells. BrdU was used to label proliferating cells.
In the spleen the total frequencies of naive B220
MenC-PS-specific B cells were comparable in mice that received MenC-PS, MenC-CRM 197 , or saline 5 days after booster (Figure 2 ). However, among B cells that had been activated by the booster to proliferate (BrdU 1 ), the frequencies of naive
MenC-PS-specific B cells (BrdU
2 ) were higher in mice that received the MenC-CRM 197 booster than in mice that received MenC-PS or saline (P , .001 and P 5 .0003, respectively) ( Figure 3 ) and was lower in mice boosted with MenC-PS than saline (P 5 .0003). These results suggest that the MenC-PS booster depleted naive MenC-PS-specific B cells in the spleen.
Mice that received MenC-CRM 197 booster showed higher total frequencies of MenC 
CD138
1 memory B cells/ plasmablasts than did mice that received MenC-PS (P 5 .011) or saline (P 5 .024), and there were no differences between the MenC-PS and saline groups (Figure 2 showed that mice that received MenC-CRM 197 booster had a higher frequency of MenC-PS-specific plasma cells than did mice that received MenC-PS booster (P 5 .0031) or saline (P 5 .016) ( Figure 2) ; however, there was no difference between the MenC-PS and saline groups. The frequencies of newly activated BrdU 1 MenC-PS-specific B220
2
CD138
1 plasma cells were lower in mice that received MenC-PS booster than in mice that received MenC-CRM 197 booster (P , .0001) or saline (P 5 .0002) (Figure 3 ), but MenC-CRM 197 booster induced higher frequencies than saline (P 5 .0006). These results indicate that the MenC-PS booster is able to activate memory B 
1 plasma cells in bone marrow than did the MenC-PS booster (P 5 .0027) or saline (P 5 .0004) (Figure 2 ), whereas no difference was found between the MenC-PS and saline groups. Mice that received MenC-CRM 197 booster also had higher frequencies of newly activated BrdU In the bone marrow there were no differences in frequencies of IgM To explain the differences in frequencies of MenC-PS-specific B cells after different boosters, AnnexinV staining was performed to study apoptosis. and 48 hours after booster. Mice that received MenC-PS showed increased apoptosis of MenC-PS-specific B cells after 8 hours and 12 hours compared with mice that received MenC-CRM 197 (8 hours, P 5 .005; 12 hours, P 5 .0286) or saline (8 hours, P 5 .0286; 12 hours, P 5 .001) ( Figure 5 and Supplementary  Figure 1 ), whereas at 24 and 48 hours the differences had disappeared (Supplementary Figure 2) . These results indicate that the differences in frequencies of MenC-PS-specific B cells 5 days after the different boosters were caused by MenC-PS-induced apoptosis of the MenC-PS-specific cells during the first 12 hours.
DISCUSSION
We have demonstrated that a booster with plain MenC-PS had a detrimental effect on MenC-PS-specific antibody responses. Accordingly, SBA was lower in mice that received MenC-PS as a second booster than in mice that received saline or . The increase in affinity and SBA after the second MenC-PS booster in the MenC-PS and saline groups may be due to the effect of the adjuvant CpG given concomitantly with the vaccines, as recent studies showed that TLR9 stimulation induces differentiation memory and transitional B cells into plasma cells [21] .
MenC-PS-induced hyporesponsiveness has been repeatedly demonstrated by serological measurements in humans and mice. The effects of MenC-PS on antibody levels, affinity, and SBA demonstrated in the current study are in agreement with the effects of MenC-PS in human infants, teenagers, and adults showing decrease in MenC-PS-specific IgG levels [3, 5-7, 22, 23] , affinity [24] , and SBA [6, 7, [22] [23] [24] .
It has been hypothesized that a MenC-PS booster depletes the memory cell pool [5, 14, 15] suggests that MenC-PS induces short-lived low-affinity plasmablasts that move to the bone marrow but do not survive [25] . AnnexinV staining of early apoptotic B cells showed that MenC-PS-specific B cells underwent increased apoptosis within the first 8-12 hours after MenC-PS booster. Polysaccharide-induced hyporesponsiveness is not limited to meningococcal serogroup C but has been observed in other serogroups [12] (reviewed in [13] ) and pneumococcal serotypes in infants [26, 27] , adults [28, 29] , and elderly persons [30] . Live pneumococci can also induce serotype-specific hyporesponsiveness in infants who are colonized before pneumococcal conjugate immunization, showing lower antibody responses to the colonizing serotypes than noncarriers [31, 32] .
It is conceivable that apoptosis as a cause of MenC-PSspecific memory-cell depletion may contribute to hyporesponsiveness induced by other PS, in mice and humans, although the extent may vary. Immunization with a conjugate vaccine may partially overcome the MenC-PS-induced hyporesponsiveness, although the quality of the antibody response to the conjugate vaccine is reduced in individuals who have received MenC-PS [9-11, 19, 33] .
Taken together, we have demonstrated directly that MenC-PS reduces the frequency of MenC-PS-specific B cells in spleen and bone marrowdin particular, the newly activated BrdU 1 IgG 1 B cells within the memory cell and plasmablast subpopulations. Furthermore, we demonstrated increased apoptosis of PS-specific B cells in the spleen within 12 hours after PS booster, which strongly suggests that PSs drive the specific memory B cells into apoptosis. This provides direct evidence for apoptosis being at least one major mechanism of PS-induced hyporesponsiveness. The recommendation of meningococcal polysaccharide vaccines for children (2-10 years) with underlying diseases, which increases their risk of invasive bacterial diseases [34] , was recently replaced by the recommendation of a quadrivalent meningococcal conjugate vaccine to all adolescents and individuals aged 2-55 years who are at increased risk of meningococcal disease [35] . The clinical relevance of PS -induced hyporesponsiveness needs to be further studied, but until it is better understood, the results presented here should be considered when designing PS-based vaccine trials and vaccination schedules.
